BioMarin Pharmaceutical Inc. (BM8.DE)
- Previous Close
81.02 - Open
80.76 - Bid --
- Ask --
- Day's Range
80.76 - 81.08 - 52 Week Range
72.40 - 108.06 - Volume
23 - Avg. Volume
18 - Market Cap (intraday)
15.262B - Beta (5Y Monthly) 0.32
- PE Ratio (TTM)
115.74 - EPS (TTM)
0.70 - Earnings Date Apr 24, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.
www.biomarin.com3,401
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: BM8.DE
Performance Overview: BM8.DE
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BM8.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BM8.DE
Valuation Measures
Market Cap
15.26B
Enterprise Value
15.23B
Trailing P/E
115.11
Forward P/E
32.57
PEG Ratio (5yr expected)
1.12
Price/Sales (ttm)
7.33
Price/Book (mrq)
3.41
Enterprise Value/Revenue
6.59
Enterprise Value/EBITDA
56.82
Financial Highlights
Profitability and Income Statement
Profit Margin
8.31%
Return on Assets (ttm)
1.78%
Return on Equity (ttm)
4.22%
Revenue (ttm)
2.47B
Net Income Avi to Common (ttm)
205.46M
Diluted EPS (ttm)
0.70
Balance Sheet and Cash Flow
Total Cash (mrq)
1.05B
Total Debt/Equity (mrq)
21.44%
Levered Free Cash Flow (ttm)
73.84M
Company Insights: BM8.DE
BM8.DE does not have Company Insights